NX-5948 demonstrated robust clinical activity with objective responses observed in 7 of 9 (77.8%) evaluable Waldenstrom’s patients in the ongoing...
WARREN, N.J., Oct. 18, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN) is a...
88% of EYLEA HD patients had a last assigned dosing interval of ≥12 weeks at week 156, while sustaining visual...
The ELEVATUM study showed clinically meaningful improvement in vision and reduction in retinal fluid in people with diabetic macular edema...
Register now to ask questions of researchers during the webinar CAPE CANAVERAL, Fla., Oct. 18, 2024 /PRNewswire/ -- The International...
The “Powering Milwaukee Forward” initiative will fund 10 Milwaukee organizations to increase access to basic needs and maternal healthcare in...
Vancouver, British Columbia--(Newsfile Corp. - October 18, 2024) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) ("PreveCeutical" or...
Presentation and live Q&A to take place Wednesday, October 23, 2024, at 12 PM EDTMarlborough, Massachusetts--(Newsfile Corp. - October 18,...
Dublin, Ireland--(Newsfile Corp. - October 18, 2024) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) shareholders today approved the...
SARASOTA, Fla., Oct. 18, 2024 (GLOBE NEWSWIRE) -- Oragenics Inc. (NYSE American: OGEN), a company focused on developing new treatments...
ZORYVE foam represents the first topical treatment for seborrheic dermatitis with a new mechanism of action approved in Canada in...
CONSHOHOCKEN, Pa., Oct. 18, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that it will release its...
Combined company will emerge as a leading global health and wellness company by providing better products and solutions for pets,...
Phase III trial results of novel triple combination pill for hypertension published in The Lancet Novel combination pill significantly reduced...
ViaNautis Bio appoints Dr Adi Hoess as Chief Executive Officer Cambridge UK, 18 October 2024 – ViaNautis Bio (“ViaNautis” or...
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY OR INDIRECTLY, IN WHOLE OR...
If approved, patients in Europe with stage II or III HR+/HER2- early breast cancer (EBC) at high risk of recurrence,...
Combined company will emerge as a leading global health and wellness company by providing better products and solutions for pets,...
Extension of 2012 agreement grants NTP the rights to manufacture and distribute non-carrier-added Lutetium-177 (n.c.a. 177Lu)Companies enter into an...
MELBOURNE, Australia, Oct. 18, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) announces that it has...